Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Diabetes Care Devices
Return to: MDBR Home | Specialty Devices | Diabetes Care Devices

Senseonics, Beta Bionics sign development agreement for Bionic pancreas system

Published 08 June 2018

Senseonics and Beta Bionics have entered into a development agreement to integrate glucose data from the Eversense continuous glucose monitoring (CGM) system into the iLet Bionic Pancreas system.

The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application.

The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion pump that mimics a biological pancreas by automatically and autonomously adapting insulin and glucagon dosing to meet the individual needs of a person with diabetes.

Senseonics president and CEO Tim Goodnow said: “We are very excited to partner with Beta Bionics to integrate our long-term glucose sensor with the bionic pancreas system.

“The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management. We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”

Beta Bionics president and CEO Ed Damiano said: “Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes.”

Under this development agreement, Beta Bionics will work with Senseonics to integrate the Eversense CGM system with the iLet, so that real-time Eversense data may serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system.

Source: Company Press Release